Back to School: How biopharma can reboot drug development. Access exclusive analysis here

NGX-4010 meets Phase III pain endpoint

NeurogesX (NGSX) said its NGX-4010 trans-capsaicin dermal patch met

Read the full 90 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE